Kairos Pharma, LTD.
KAPA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962011
No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.
Holders of 5% or more of KAPA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kairos Pharma, LTD., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Kairos Pharma, LTD. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Kairos Pharma, LTD., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20259:12 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 4.99%884.9K shares | −5.00 ppfrom 9.99%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20253:19 PM ET | Armistice Capital, LLCand 1 other | 13G | 9.99%1.70M shares | New | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Kairos Pharma, LTD. shares.
No Form 144 notices for Kairos Pharma, LTD. are on file.